Curtis A Engelhart
Overview
Explore the profile of Curtis A Engelhart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Green S, Harrison J, Thompson S, Murugesan D, Libardo M, Engelhart C, et al.
ACS Infect Dis
. 2025 Feb;
11(3):715-726.
PMID: 40014668
Although not currently in the infectious disease spotlight, there is still a pressing need for new agents to treat tuberculosis caused by . As there is an ever-increasing amount of...
2.
Liu Q, Engelhart C, Wallach J, Tiwari D, Ge P, Manna A, et al.
J Med Chem
. 2025 Jan;
68(3):3065-3087.
PMID: 39823202
The antibacterial agent Bio-AMS is metabolized in vivo through hydrolysis of the central acyl-sulfamide linker leading to high clearance and release of a moderately cytotoxic metabolite . Herein, we disclose...
3.
Krieger I, Yalamanchili S, Dickson P, Engelhart C, Zimmerman M, Wood J, et al.
ACS Infect Dis
. 2024 Apr;
10(5):1561-1575.
PMID: 38577994
DNA-encoded chemical library (DEL) technology provides a time- and cost-efficient method to simultaneously screen billions of compounds for their affinity to a protein target of interest. Here we report its...
4.
Green S, Wilson C, Eadsforth T, Punekar A, Tamaki F, Wood G, et al.
J Med Chem
. 2023 Nov;
66(22):15380-15408.
PMID: 37948640
There is an urgent need for new tuberculosis (TB) treatments, with novel modes of action, to reduce the incidence/mortality of TB and to combat resistance to current treatments. Through both...
5.
Sharma R, Hartman T, Beites T, Kim J, Eoh H, Engelhart C, et al.
mBio
. 2023 Jun;
14(4):e0034023.
PMID: 37350592
Nicotinamide adenine dinucleotide (NAD) and its phosphorylated derivative (NADP) are essential cofactors that participate in hundreds of biochemical reactions and have emerged as therapeutic targets in cancer, metabolic disorders, neurodegenerative...
6.
Hegde P, Orimoloye M, Sharma S, Engelhart C, Schnappinger D, Aldrich C
Tuberculosis (Edinb)
. 2023 Apr;
140:102346.
PMID: 37119793
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) is a leading cause of infectious disease mortality. The salicylic acid derived small molecule siderophores known as mycobactins are essential in vivo for...
7.
Green S, Davis S, Damerow S, Engelhart C, Mathieson M, Baragana B, et al.
Nat Commun
. 2022 Oct;
13(1):5992.
PMID: 36220877
Tuberculosis is a major global cause of both mortality and financial burden mainly in low and middle-income countries. Given the significant and ongoing rise of drug-resistant strains of Mycobacterium tuberculosis...
8.
Li S, Poulton N, Chang J, Azadian Z, DeJesus M, Ruecker N, et al.
Nat Microbiol
. 2022 May;
7(6):766-779.
PMID: 35637331
Mycobacterium tuberculosis (Mtb) infection is notoriously difficult to treat. Treatment efficacy is limited by Mtb's intrinsic drug resistance, as well as its ability to evolve acquired resistance to all antituberculars...
9.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, MacKenzie C, et al.
J Med Chem
. 2021 Dec;
65(1):409-423.
PMID: 34910486
With increasing drug resistance in tuberculosis (TB) patient populations, there is an urgent need for new drugs. Ideally, new agents should work through novel targets so that they are unencumbered...
10.
Bosch B, DeJesus M, Poulton N, Zhang W, Engelhart C, Zaveri A, et al.
Cell
. 2021 Jul;
184(17):4579-4592.e24.
PMID: 34297925
Antibacterial agents target the products of essential genes but rarely achieve complete target inhibition. Thus, the all-or-none definition of essentiality afforded by traditional genetic approaches fails to discern the most...